Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study

BMC Cancer

Qing-An Zeng¹  Jiliang Qiu²  Ruhai Zou²  Yijie Li¹  Shengping Li²  Binkui Li²  Pinzhu Huang²  Jian Hong²  Yun Zheng²  Xiangming Lao²  Yunfei Yuan² 

[1] Department of General Surgery, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China

[2] State Key Laboratory of Oncology in South China/Department of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, China

关键词: Prognosis;    Hepatocellular carcinoma;    Extrahepatic;    Multiple primary;    Neoplasm;   

Others  :  1080459
DOI  :  10.1186/1471-2407-12-148

 received in 2011-09-25, accepted in 2012-04-17,  发布年份 2012

【 摘 要 】

Background

The prolonged survival of individuals diagnosed with cancer has led to an increase in the number of secondary primary malignancies. We undertook to perform a definitive study to characterize and predict prognosis of multiple primary malignancies (MPM) involving hepatocellular carcinoma (HCC), due to the scarcity of such reports.

Methods

Clinicopathological data were analyzed for 68 MPM patients involving HCC, with 35 (target group) underwent curative liver resection. Additional 140 HCC-alone patients with hepatectomy were selected randomly during the same period as the control group.

Results

Of the 68 patients with extrahepatic primary malignancies (EHPM), 22 were diagnosed synchronously with HCC, and 46 metachronously. The most frequent EHPM was nasophargeal carcinoma, followed by colorectal and lung cancer. Univariate analysis demonstrated that synchronous (P = 0.008) and non-radical treatment for EHPM (P < 0.001) were significant risk factors associated with poorer overall survival (OS). While, Cox modeling revealed that the treatment modality for EHPM, but not the synchronous/metachronous determinant, was an independent factor for OS, and that therapeutic option for HCC was an independent factor for HCC-specific OS. Moreover, no HCC-specific overall and recurrence-free survival benefit were observed in the control group when compared with that of the target group (P = 0.607, P = 0.131, respectively).

Conclusions

Curative treatment is an independent predictive factor for OS and HCC-specific OS, and should been taken into account both for synchronous and metachronous patients. MPM patients involving HCC should not be excluded from radical resection for HCC.

【 授权许可】

   
2012 Zeng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. Ca-a Cancer Journal for Clinicians 2005, 55(2):74-108.
• [2]Shimada M, Takenaka K, Fujiwara Y, Gion T, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K: Characteristics of hepatocellular carcinoma associated with extrahepatic primary malignancies in southern Japan. Am J Gastroenterol 1996, 91(4):754-758.
• [3]Nzeako UC, Goodman ZD, Ishak KG: Association of hepatocellular-carcinoma in North-American patients with extrahepatic primary malignancies. Cancer 1994, 74(10):2765-2771.
• [4]Takayasu K, Kasugai H, Ikeya S, Muramatsu Y, Moriyama N, Makuuchi M, Yamazaki S, Hirohashi S: A clinical and radiologic study of primary liver-cancer associated with extrahepatic primary-cancer. Cancer 1992, 69(1):45-51.
• [5]Kanematsu M, Imaeda T, Yamawaki Y, Hirose Y, Inoue A, Goto H, Doi H: Hepatocellular-carcinoma with extrahepatic primary neoplasms. Gastrointest Radiol 1992, 17(1):53-57.
• [6]Lin DY, Liaw YF, Wu CS, Changchien CS, Chen PC, Chen TJ: Hepatocellular-carcinoma associated with 2nd primary malignancy. Liver 1987, 7(2):106-109.
• [7]Riesz T, Jako JM, Juhasz J: Secondary malignant-tumors accompanied by primary hepatocellular carcinoma. Acta Hepato-Gastroenterologica 1979, 26(5):364-367.
• [8]Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127(5 Suppl 1):S5-S16.
• [9]Jensen OM, Storm HH: Cancer registration: principles and methods. Reporting of results. IARC Sci Publ 1991, 95:108-125.
• [10]Ecimovic P, Pompe-Kirn V: Second primary cancers in laryngeal cancer patients in Slovenia, 1961–1996. Eur J Cancer 2002, 38(9):1254-1260.
• [11]Aydiner A, Karadeniz A, Uygun K, Tas S, Tas F, Disci R, Topuz E: Multiple primary neoplasms at a single institution: differences between synchronous and metachronous neoplasms. Am J Clin Oncol 2000, 23(4):364-370.
• [12]Eom BW, Lee HJ, Yoo MW, Cho JJ, Kim WH, Yang HK, Lee KU: Synchronous and metachronous cancers in patients with gastric cancer. J Surg Oncol 2008, 98(2):106-110.
• [13]Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, Bepler G: Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008, 26(7):1142-1147.
• [14]Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003, 362(9399):1907-1917.
• [15]Czaja AJ, Freese DK: Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002, 36(2):479-497.
• [16]Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ: Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 2007, 16(3):566-571.
• [17]Guerin S, Guibout C, Shamsaldin A, Dondon MG, Diallo I, Hawkins M, Oberlin O, Hartmann O, Michon J, Le Deley MC, et al.: Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: a case–control study. Int J Cancer 2007, 120(1):96-102.
• [18]Allan JM, Travis LB: Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005, 5(12):943-955.
• [19]Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, et al.: Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002, 20(16):3484-3494.
• [20]Lee KD, Chen SC, Chan CH, Lu CH, Chen CC, Lin JT, Chen MF, Huang SH, Yeh CM, Chen MC: Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan. Cancer Epidemiol Biomarkers Prev 2008, 17(10):2647-2655.
• [21]Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, Meadows AT: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996, 334(12):745-751.
• [22]Chaturvedi AK, Engels EA, Gilbert ES, Chen BE, Storm H, Lynch CF, Hall P, Langmark F, Pukkala E, Kaijser M, et al.: Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007, 99(21):1634-1643.
• [23]Fernandez-Ruiz M, Guerra-Vales JM, Castelbon-Fernandez FJ, Llenas-Garcia J, Caurcel-Diaz L, Colina-Ruizdelgado F: Multiple primary malignancies in Spanish patients with hepatocellular carcinoma: analysis of a hospital-based tumor registry. J Gastroenterol Hepatol 2009, 24(8):1424-1430.
• [24]Kaczynski J, Hansson G, Wallerstedt S: Hepatocellular carcinoma and extrahepatic primary malignancy. J Hepatol 1995, 23(5):628-629.
• [25]Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
• [26]Zhang SW, Lei ZL, Li GL, Zou LN, Zhao P, Chen WC: A report of cancer incidence and mortality from 34 cancer registries in China, 2006. Chin Cancer 2010, 19(6):356-365.
• [27]Jia WH, Luo XY, Feng BJ, Ruan HL, Bei JX, Liu WS, Qin HD, Feng QS, Chen LZ, Yao SY, et al.: Traditional Cantonese diet and nasopharyngeal carcinoma risk: a large-scale case–control study in Guangdong, China. BMC Cancer 2010, 10:446. BioMed Central Full Text
• [28]Rydzanicz M, Wierzbicka M, Gajecka M, Szyfter W, Szyfter K: The impact of genetic factors on the incidence of multiple primary tumors (MPT) of the head and neck. Cancer Lett 2005, 224(2):263-278.
• [29]Lim JH, Choi D, Kim SH, Lee SJ, Lee WJ, Lim HK, Kim S: Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. American Journal of Roentgenology 2002, 179(1):67-73.